- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Quality Registries in Dementia Care: Mapping of Registries to improve Quality and Service Delivery
QRs in dementia care are systems to support decision-makers and healthcare planners in developing optimal dementia care pathways while improving the quality of dementia care services and patient outcomes. The aim of the report was to analyse dementia QRs and to provide an overview of the quality indicators used including the underlying evidence. In addition, the empirical results from the identified dementia QRs, in combination with good registry practice from the literature, were embedded into a good practice framework.
Publication: HTA Project Report No. 150: https://eprints.aihta.at/1419/
Contact: Christoph Strohmaier
Announcement
Child and adolescent mental health care models
Mental disorders in children and adolescents are among the most common illnesses with a high burden of disease. The increasing need for care with simultaneous bottlenecks in health services leads to considerations for other care and prevention models. In this context, in this research report international models for prevention and care for child and adolescent mental health were analysed. In addition, an overview of relevant indicators specifically for this population was compiled. Based on these international recommendations, possibilities for the further development of the current Austrian care structures were identified.
Publication: HTA Project Report No. 149: https://eprints.aihta.at/1418/
Contact: Reinhard Jeindl
Announcement
Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements
Osteopathy aims to holistically improve and support all aspects of health. Osteopathic treatments are often applied for pain in the musculoskeletal system. In Austria, there is no legal regulation for the practice, education and training of osteopaths, while other countries have already introduced regulations. The report aims to summarise evidence on the effectiveness and safety of osteopathy in the treatment of musculoskeletal pain and to provide an overview of the training and quality requirements and regulations for the osteopathic profession in Europe.
Publication: HTA Project Report No. 144: https://eprints.aihta.at/1416
Contact: Lucia Gassner
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Internationale Trends in der Krankenhausfinanzierung
- CAR-T Zelltherapie: Kontrastierung der Evidenz aus Zulassungsstudien mit Versorgungsstudien
- Modelle zur Prävention und Versorgung psychischer Erkrankungen bei Kindern und Jugendlichen
- Osteopathie bei Schmerzen des Bewegungs- und Stützapparates und Überblick über Ausbildungs- und Qualitätsanforderungen
- Qualitätsregister in der Demenzversorgung
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v24 October/November2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Announcement
CAR-T cell therapy: Contrasting the evidence from pivotal trials with the real world evidence (RWE)
The two CAR-T cell therapies Kymriah® and Yescarta® were approved by the EMA in 2018 for patients with B-cell acute lymphoblastic leukaemia (B-ALL), diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL) in third line. Treatment is often associated with high expectations, but the evidence on efficacy and safety of these novel therapies is still uncertain. The aim of this systematic review was to contrast the results of patient characteristics as well as selected efficacy and safety endpoints from the pivotal trials with those from real-world evidence studies. In addition, the results and conclusions of other HTA reports were summarised regarding the available evidence on efficacy and safety.
Publication: HTA Project Report No. 146: https://eprints.aihta.at/1415/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 112 (November 2022)
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)
Fact Sheet No. 113 (November 2022)
Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer
Fact Sheet No. 114 (November 2022)
Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 109 (October 2022)
Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)
Fact Sheet No. 110 (October 2022)
Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)
Fact Sheet No. 111 (October 2022)
Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: De-Eskalation: EORTC legt Konzept zur Optimierung (statt Maximierung) onkologischer Therapien vor
- Pilotierung des „Village Programms“ zur Unterstützung von Kindern mit psychisch erkrankten Eltern in Tirol
- Zytoreduktive Chirurgie (CRS) und hypertherme intraperitoneale Chemotherapie (HIPEC) bei sekundärer Peritonealkarzinose
- Long-Covid Versorgungspfade
- Defibrillator-Weste (WCD) zur Prävention des plötzlichen Herztodes
- Termine
- Themen-Vorschau
Announcement
Long COVID care pathways and structures: an updated scoping review
Long COVID can impact the patients' everyday functioning, including long absenteeism in school or work. As a result, the disease not only places a burden on patients and their families but also on the economy, especially the labour market. The present scoping review aimed to update the recommendations on care pathways for adult long COVID patients and add recommendations for children and adolescents. In addition, it presents further existing long COVID care structures of selected European countries.
Publication: HTA Project Report No. 135b Update: https://eprints.aihta.at/1408/
Contact: Sarah Wolf
